Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.
Dr. Peter T. Meinke, an accomplished chemist with more than 30 years of industry and academic experience, has been selected to lead the Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI).